Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504219 | 0.87 | PIK3CA (0.36) | CCR3 | |
| SCHEMBL6493927 | 0.83 | HTR2C (0.32) | — | |
| SCHEMBL6503481 | 0.83 | CCR3 (0.31) | CCR3 | |
| SCHEMBL6810041 | 0.78 | TYK2 (0.35) | — | |
| SCHEMBL6503483 | 0.76 | RAF1 (0.31) | — | |
| SCHEMBL6490580 | 0.72 | DRD2 (0.34) | CCR3 | |
| SCHEMBL6494306 | 0.72 | HTR2A (0.36) | — | |
| SCHEMBL6810428 | 0.72 | DRD2 (0.34) | CCR3 | |
| SCHEMBL6490962 | 0.72 | KDM1A (0.32) | — | |
| SCHEMBL6501085 | 0.70 | HTR2C (0.41) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908932-B2 | Cancer therapy | ICONIX PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-6849619-B2 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | ENTELOS HOLDING CORP. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186094-A1 | Substituted pyridoindoles as serotonin agonists and antagonists | HTR1A, HTR1B, HTR7 | CCR3 3424/4885FASN 2769/4885 |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | PIK3R1, PIK3R3, PIK3R4 | CCR3 1075/4885FASN 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.